bluebird bio Inc (NAS:BLUE)
$ 0.4171 0.0121 (2.99%) Market Cap: 81.10 Mil Enterprise Value: 376.50 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 31/100

bluebird bio Inc to Provide Updated Findings from Reported Case of Acute Myeloid Leukemia (AML) in LentiGlobin for Sickle Cell Disease (SCD) Gene Therapy Program - Conference Call Transcript

Mar 10, 2021 / 01:00PM GMT
Release Date Price: $21.03 (+8.12%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the bluebird bio conference call. (Operator Instructions)

I would now like to hand the conference over to your speaker today, Ms. Liz Pingpank. Ma'am, the floor is yours.

Elizabeth Pingpank
bluebird bio, Inc. - Director of Corporate Communications

Thank you. Good morning, everyone, and thank you for joining today's call to discuss an update into the investigation of recent adverse events reported in our HGB-206 study. On today's call, Nick and Philip will discuss the updates and will be joined in Q&A by Dave and Chip.

Before we begin, we would like to remind everyone that as part of this conversation, we will be making statements about ongoing investigation into 2 safety events in the HGB-206 clinical study disclosed on February 16, including our plans for further investigation and potential regulatory interactions in sickle cell disease and beta thalassemia. These statements constitute forward-looking statements and represent our views as of today and should not be relied

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot